| Instructions for Contributors
REVIEW PROCESS AND POLICIES
Experimental Hematology welcomes
submissions in the categories listed
below. Each submitted manuscript will undergo peer review by at least
two editorial board members
or other experts designated by the editor-in-chief
or associate editor in charge of the manuscript's review. Authors'
names will be seen
by reviewers, but reviewers' names will not be disclosed
to the authors. A paper can be rejected without undergoing the peer
review process
if the editor determines that the content is inappropriate for
the journal. Authors usually receive the editorial decision within 4 to
6 weeks
of their manuscript's arrival at the editorial office.
The editorial office assigns a manuscript number and acknowledges
receipt of submission within 3 days of receipt. Papers
submitted by editors or editorial board members are subjected to the same
rigorous
standards as other manuscripts. An editor who submits a manuscript
for consideration does not have access to the reviewers' identities
or their confidential remarks for that submission.
Regular Submissions: These are full-length reports of original research
involving in vivo and ex vivo studies in the following areas: cell cycle regulation,
clinical investigations, cytokines, erythropoiesis,
gene therapy, general hematopoiesis,
granulopoiesis, hematological malignancies, immunobiology, immunotherapy,
lymphopoiesis, megakaryocytopoiesis,
microenvironment, monocyte
development, molecular genetics, signal transduction, stem cell biology,
and experimental as well as clinical
stem cell transplantation.
We also welcome reports investigating the concept of "stem cell plasticity,"
including those involving
stem cells from sources other than marrow
and blood. We welcome studies regarding the phenotype and growth factor
requirements of stem
cells; studies addressing homing and engraftment as
well as functional reconstitution of stem cells; and fundamental investigations
regarding
the nature of transdifferentiation and dedifferentiation.
Letters to the Editor: Letters to the editor may relate to material
published
in the journal, to ISEH business, editorial policy, or anything else
pertinent to the field of experimental hematology. A letter
that addresses
an article published in this journal should be submitted as soon as possible,
no later than two calendar months after
publication. Such a letter will
be sent to the authors of that paper for a possible reply. All letters and
their replies are published
at the editor's discretion and are subject to
peer-review. Letters should not exceed 1,000 words. Figures and tables
cannot be included,
and no more than 10 references may be used.
CONFLICT OF INTEREST POLICY
A conflict of interest exists when an author,
reviewer, or editor has financial or personal relationships with other persons or organizations that may inappropriately influence or
bias his or her actions. There is a potential for a conflict of interest whether or not an individual believes that a relationship affects
his or her scientific judgment. Conflicts can occur as the result of employment, consultancies, stock ownership, honoraria, paid expert
testimony or opinions, personal and family relationships, or academic competitive pressures. All participants in the peer review and
publication process must disclose all relationships that could be viewed as a potential conflict of interest.
Potential Author
Conflicts
Authors should disclose at the time of manuscript submission all financial and interpersonal relationships that could
be viewed as presenting a potential conflict of interest. These include, but are not limited to, any financial relationship that involves
conditions or tests or treatments discussed in the manuscript or alternatives to tests or treatments. Authors should disclose information
even when there is a question as to whether a relationship constitutes a conflict. Potential conflicts should be listed for each author
on the page following the title page; a summary of relevant information will be published with the manuscript.
Authorship of editorials
and reviews requires interpretation of the literature and therefore is inherently subject to bias, thus authors of such manuscripts should
not have a significant financial interest in the subject matter of the manuscript
MANUSCRIPT SUBMISSION
Experimental
Hematology utilizes Editorial Manager™, a web-based
manuscript submission and peer-review system. Authors should
submit
their manuscripts, with figures and tables, electronically at theExperimental Hematology website, www.exphem.org.
Authors can also
visit www.editorialmanager.com/exphem. Complete
instructions are
available at the website. If authors do not receive an email confirmation of
submission within 24 hours, it may be an
indication that the manuscript
has not been received by the editorial office. If authors experience any
difficulty during the submission
process or require any assistance, please
contact the editorial office at exphem@cabnr.unr.edu.
We strongly encourage
all authors and reviewers to use Editorial
Manager™ when submitting manuscripts to the journal. Should you
presently
be unable to take advantage of online submission and review
please continue to submit your work to us offline (via mail or email). Our
editorial office will make proxy submissions of all manuscripts accompanied
by a diskette containing the electronic files of the text,
tables, and figures.
Please note that original sources files, not PDF files, are required. Once
the submission files are uploaded, the
system automatically generates an
electronic (PDF) proof which is then used for reviewing. All correspondence,
including the Editor's
decision and request for revisions, will be sent
via e-mail.
If submitting your manuscript offline, submit one original of the text,
tables, and figures prepared according to the instructions below with the
cover letter, statement of authorship, in-press references,
permission
statements (if applicable), computer disk, and submission fee to Esmail
D. Zanjani, PhD, Editor, at the editorial office address
listed at the end of
this document.
Authors outside North America take heed: manuscripts sent by airmail
instead of courier (e.g.,
DHL, Federal Express, etc.) can take up to 5 weeks
to arrive at the editorial office.
Reviewers: Authors are encouraged to
suggest several potential reviewers without conflicts of interest, including at least one member of the journal's editorial board.
When submitting your manuscript electronically through Editorial Manager, both suggested and opposed reviewers can be identified as
part of the submission process. If a manuscript is submitted outside of the Editorial Manager system, suggested and opposed reviewers
should be identified in the cover letter accompanying the manuscript.
Statement of Authorship: Authors are also required to
fill out an Authorship Statement form at the time of manuscript submission. The statement must include the names and signatures of ALL
authors who have contributed significantly to the research described in the paper and have read and approved the final manuscript. The
Authorship Statement form is available at the Experimental Hematology Editorial Manager website homepage (www.editorialmanager.com/exphem). It must be submitted off-line by either mail or fax to the editorial office address listed at the end of this
document.
Computer Disk: All authors submitting their work off-line should
include electronic versions of their manuscripts
on CDs (preferred) or
3.5-inch floppy (HD/DD) disks. Microsoft Word® and PowerPoint® are
accepted. Make certain that the electronic
and paper copies match
exactly. Specify the software used, including the release (e.g., Word for
Windows 2000) and OS (Macintosh or PC).
The text file should include text, references, tables, and figure captions. Figures should be saved as separate files (preferably as
TIFF or other high resolution file format). Be sure to keep a back-up disk for
reference and safety. Disks will not be returned.
Manuscript
Length: Write succinctly. Authors are urged to keep the
word count of their papers (excluding references, figure legends, and tables)
to less than 3,600 words. Longer papers of scientific merit will not
be excluded from publication, but should still be as concise as
possible.
CHARGES TO AUTHORS
Authors pay the following
charges:
- Experimental Hematology requires a submission
fee of $50.00 USD to process Regular Submissions (not applicable for Letters to the Editor or Invited Review articles). Current
members of ISEH are not required to pay the submission fee when they are the corresponding author of the submission. You may pay by check
or credit card. If paying by check, please make checks payable to the ISEH and mail to the Editorial Office address listed at the end
of this document. To pay the submission fee by credit card please click on the manuscript submission fee link on the Experimental Hematology
Editorial Manager website homepage (www.editorialmanager.com/exphem).
Please note that we cannot release the editorial decision if we have not received the submission fee.
- Page charges for manuscripts
(as of the June 2003 issue) $50 per page
for the first eight published pages or portions thereof, and $160 for
each additional
page over eight or portion thereof, plus tax (except for
employees of nonprofit institutions who provide tax-exempt numbers
at time of
payment).
- Expense for color reproduction of figures: $650 for the first figure and$100 for each additional figure,
plus tax (except for employees of nonprofit
institutions who provide tax-exempt numbers at time of payment).
- Expense for offprints.
The publisher will send the corresponding author
the price quotation with the page proofs.
MANUSCRIPT PREPARATION
Note for those submitting your work online using Editorial Manager™:
this system will guide you through all of the steps
for submitting your
article to Experimental Hematology. Please type manuscripts doublespaced
with 10- or 12-point type-including
references, figure legends,
and tables?on one side of the page only. Please type the page number on
every page. Leave 1.25-inch margins
on all sides, and do not use justified
margins. European authors using A4-size paper: please leave a 2.5-inch
margin on the bottom of
the page.
Title Page: The first page of the manuscript must include (1) the title (the title should accurately reflect the
manuscript's content), (2) the full names of all authors, (3)
each author's institutional affiliations, (4) the corresponding author's
courtesy title (Prof. or Dr.), full name, credentials (MD, PhD), complete
mailing address, telephone and fax numbers, and e-mail address,
(5) contact
information for offprints if different from that of the corresponding author,
(6) the Table of Contents category that best
describes the manuscript's topic:
Cell Cycle Regulation, Clinical Investigations, Cytokines, Erythropoiesis,
Gene Transfer/Gene Therapy,
General Hematopoiesis, Granulopoiesis,
Hematological Malignancies, Immunobiology, Immunotherapy, Lymphopoiesis,
Megakaryocytopoiesis,
Microenvironment, Monocyte Development,
Molecular Genetics, Signal Transduction, Stem Cell Biology, Stem
Cell Plasticity, or Stem Cell
Transplantation, and (7) the paper's word count
(excluding references, figure legends, and tables).
For manuscripts about clinical
studies, use the category of "Clinical
Investigation." If your manuscript's topic does not fit within one of these
categories, it may
not be within the journal's scope. Contact the editorial
office for confirmation before submitting the manuscript.
Abstract:
The second page of the manuscript should present an abstract
of no more than 250 words under the following headings: (1) Objective,
(2)
Methods (or Patients and Methods, Materials and Methods, etc.), (3)
Results, and (4) Conclusion. Please include a short list of key
words. Where possible, consider using MESH terms. For a list of MESH terms please visit  http://www.nlm.nih.gov/mesh/ .
Do not cite references.
Text: The body of the paper should begin on the third page and conform
to the "Style Guidelines" described
below. Do not include a summary at
the end of the text. Cite each figure and table in the text in numerical order.
Cite each reference
in the text in numerical order and list in the References
section. In the text, set the reference numbers in brackets. In-text
reference
numbers may be repeated but not omitted. Authors who are not
fluent in English are strongly advised to seek editorial help from a colleague
before submitting their papers.
Support and Financial Disclosure Declaration
List all sources of support for research (from
funding agencies or industry) and disclose any potential financial conflicts of interest (relevant consulting fees, stock options, employment,
etc) for each author. If no financial conflict of interest is identified, 'none' should be written next to the author name.
Note:
If the manuscript is accepted for publication, a summary of the relevant information will be transferred to the Acknowledgements section.
Acknowledgements
If authors wish to express thanks or acknowledge substantive contributions or assistance of individuals
who are not authors, this should be included in the Acknowledgments section after the manuscript text and before the reference list.
Authors are responsible for informing all named individuals/parties that they are being mentioned in their submitted manuscript and
obtaining their approval prior to publication.
References: Include only published materials or those accepted for publication
(in press) in the reference list. Cite references in numerical order
according to first mention in the text. Verify all entries against
original
sources, especially journal titles, publication dates, accents, diacritical
marks, and spelling in languages other than English.
All listed references must be cited in the text.
Journal titles should be abbreviated according to titles listed in Index
Medicus.
Cite abstracts only if they are the sole source.References should include complete page ranges.
Follow these models when organizing
references:
- For a journal article with up to 6 authors, list all authors:
Fraser ST, Ogawa M, Yu RT, Nishikawa S, Yoder
MC, Nishikawa S-I.
Definitive hematopoietic commitment within the embryonic vascular
endothelial-caderin+ population. Exp
Hematol. 2002;30:1061-1069.
- For a journal article with more than 6 authors, list the first 3 authors,
followed by et al.:
Berries VM, Dooner GJ, Nowakowski G, et al. The molecular basis
for the cytokine-induced defect in homing and engraftment of hematopoietic
stem cells. Exp Hematol. 2001;29:1326-1335.
- For a journal article in press:
Riley RL, Knowles J, King AM. Levels of E2A
protein expression in
B cell precursors are stage-dependent and inhibited by stem cell factor
(c-kit ligand). Exp Hematol. In press.
- For a chapter in a book:
Munshi NC, Tricot G, Barlogie B. Plasma cell neoplasms. In: DeVita
Jr. VT, Hellman S, Rosenberg
SA, eds. Cancer: Principles & Practice
of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins;
2001. p. 2491-2493.
- For an abstract or letter:
Roberts A, Croker B, Handman E, Williams D, Tarlinton D. Rac2
Regulates T and B Lymphocyte Chemotaxis,
Distribution and Function
[abstract]. Exp Hematol. 2002;30(suppl 1):143. Abstract 427.
For other formats, please follow the
recommendations of the International
Committee of Medical Journal Editors at http://www.icmje.org/ . (this will help those
individuals utilizing referencing software.)
Unpublished observations and personal communications cannot be included
in the References
section, although they may be cited in the text as
"(unpublished data, year)." Papers that rely on such citations for details
that are
essential for critical review of the manuscript may be rejected.
For personal communications, the permission of the individual who communicated
the data is required.
Figures: Prepare artwork using professional standards and photographed as
camera-ready, unmounted, glossy
prints if color, halftones, or photomicrographs.
Glossy prints of line drawings, graphs, etc. are not required if good
quality computer-generated
laser prints (not photocopies) are submitted.
Figures should be created at the highest resolution possible and saved as individual
files. Photographic figures should not be mounted. Indicate the figure number unobtrusively in the lower right corner of each page containing
a line drawing, graph, or other laser-printed art. For photomicrographs, indicate the figure number and the orientation with an arrow
on the back. Figures that are grouped together must match in size, particularly in height, and be uniform in style and size of lettering.
Supply a scale bar with photomicrographs.
Proofread all text in the figures and ensure that all figure components
are clearly distinguishable
from each other (e.g., bar graph hatchings).
Ensure that the body of the paper does not repeat data reported in figures.
Figure
Legends: Provide double-spaced text for figure legends on separate
pages within the manuscript. Include a title for each figure and
define
any acronyms, abbreviations, initialisms, or symbols used in the
figures.
Tables: Begin each table on a separate page
in
double-spaced type. Title the table with "Table" and the Arabic numeral,
followed by a period and a brief informative title. Use the
same size type
as in the text.
Indicate footnotes in the table in this order: 
Do not use vertical lines in tables. Use horizontal lines above and below
the column headings and at the bottom of the table only.
Use extra space
to delineate sections within the table.
Ensure that the text does not duplicate data reported in tables. Provide a
legend defining all acronyms, abbreviations, and initialisms.
Previously Published Material: For manuscripts containing tables
or
figures adapted or reproduced from other sources, submit signed statements
from both the author and the publisher giving permission
to Experimental
Hematology for usage. Also, acknowledge the original source in
the table or figure legend. Permission is required
irrespective of authorship
or publisher, except for documents in the public domain.
STYLE GUIDELINES
Abbreviations:
All abbreviations must be defined the first time that they
are used in the text.
Distribution of reagents: By publishing in
this journal, authors imply
that they will make freely available to other academic researchers any easily
provided materials (e.g., cells,
clones of cells, antibodies, DNA probes,
nucleic acid sequences, or genetic strains of animals) that were used in the
research reported
and that are not available from commercial suppliers.
Drugs: Trade names, spelled exactly as trademarked and with the initial
letter capitalized, may be used after a drug has been identified once by its
generic name or by its systematic chemical name. Unfamiliar
compounds
other than drugs must also be designated, when first issued, by their correct
systematic names. Systematic chemical names should
conform to the
usage given in the indexes of Chemical Abstracts.
Human Experimentation: In experimental studies with human
subjects,
details of age, race, and sex of the subject must be included. There
must also be a statement that informed consent was obtained
from the
subjects and that the investigations had been approved by an institutional
Human Research Committee. In addition, safeguards
for protection of the
rights of minors and mentally impaired subjects should be stated. In all
material, patients must be identified
by number or serial letter and not by
initials or names. If the manuscript requires photographs of faces or other
identifiable body parts
or detailed case descriptions, authors must obtain
written consent from the identifiable subject and provide a copy of the
permission
with the manuscript upon submission.
Manufacturers: Include the name of the pharmaceutical or equipment
company, as well as
the city, state or province, and country, in parentheses
after the first mention of every material used.
Mathematical Notation:
Use typewritten letters, numbers, and symbols
whenever possible. Identify boldface, script letters, etc., at their first
occurrence.
Distinguish between one and the letter "I" and zero and the
letter "O" whenever confusion might result.
Any data previously published
in any form (except abstracts) must be
clearly identified as such.
Measurements: Use metric system and Celsius degrees; use
L for liter.
Nomenclature and Symbols: Follow the recommendations of the International
Union of Pure and Applied Chemistry
(IUPAC) and the International
Union of Biochemistry (IUB). In respect to molecular regulators
of hemopoiesis that are either essential
for proliferation and differentiation
of a given cell line or potentiate the action of a specific regulator, sufficient
information should
be given in respect to its molecular weight,
chemical characteristics, stability, resistance to enzymatic digestion,
method of assay,
etc., so that others can appreciate the basic properties.
When a regulatory molecule has been purified to homogeneity, sequenced,
cloned,
and produced as a pure entity, the name then given to the humoral
regulator should be used. When there are numerous synonyms, these
should
be listed once. Until there is a consensus in respect to nomenclature,
authors may use the names they prefer.
Statistical Analyses:
In respect to bioassay or radioimmunoassay, potency
estimates should be accompanied by a measure of the precision of
these estimates.
Both bioassays and radioimmunoassays should be precision-related to within-assay variability and to the variability measurements
or subsequent
independent assays. When data are insufficient to determine
whether the data conform to a normal or other distribution, it is more appropriate
to use nonparametric tests of significance. Manuscripts must describe
novel methods, models, and approaches to statistical analysis concisely,
but
in sufficient detail to allow evaluation of the results reported.
Recombinant DNA: With the use of "recombinant" material
in research,
particularly with recombinant viral vectors that may infect human
cells, investigators must include a statement regarding
the containment
category of genetically engineered organisms. Procedures and safeguards
must be specified for the construction and handling
of recombinant DNA
molecules and organisms and viruses containing recombinant DNA.
COPYRIGHT
All material that is accepted
for publication becomes the sole property of
the ISEH. Authors must sign a copyright transfer form upon acceptance
of any material for
publication. The ISEH does, however, grant the authors
the right to reproduce tables and figures from their articles published
by the
ISEH in the author's future publications.
EDITORIAL OFFICE
For more information, contact the journal's managing editor,
Kimberly A.
Higgins, at the address below:
Esmail D. Zanjani, PhD
Editor-in-Chief, Experimental Hematology
University
of Nevada, Reno
Dept. of Animal Biotechnology M/S 202
1664 N. Virginia Street
Reno, NV 89557 USA
Phone: (775) 784-7735
Fax: (775) 784-7736
E-mail: exphem@cabnr.unr.edu
Updated December 2009
|
